secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001558370-23-017313
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virios provides pipeline update: IMC-1 Phase 3 partnership discussions, IMC-2 FDA briefing for Long-COVID
--------------------------------------------------------------------------------

- FDA guidance received for IMC-1 Phase 3 fibromyalgia trial; multiple life science companies reviewing Phase 2 data for partnership.
- Briefing materials submitted to FDA for IMC-2 Investigational New Drug application to treat Long-COVID (no approved LC treatments yet).
- Filed provisional method-of-use patents for IMC-2 in Long-COVID and Alzheimer's disease, covering through at least 2043.
- Cash runway expected to support operations into Q3 2024 due to expense management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837023017313/0001558370-23-017313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837023017313/tmb-20231102x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-017313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer